Clinic of Radiation Oncology, Mersin Education and Research Hospital, Mersin, Turkey.
Department of Radiation Oncology, Medical Faculty, Baskent University, Adana, Turkey.
Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231187759. doi: 10.1177/03946320231187759.
The objective of our study was to assess the prognostic significance of the Pan-Immune-Inflammation Value (PIV) before concurrent chemoradiation (C-CRT) and prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer (SCLC). The medical records of LS-SCLC patients who underwent C-CRT and PCI between January 2010 and December 2021 were retrospectively analyzed. PIV values were calculated using the peripheral blood samples obtained within the past 7 days before the initiation of treatment: PIV = [neutrophils × platelets × monocytes] ÷ lymphocytes. Using receiver operating characteristic (ROC) curve analysis, the optimal pretreatment PIV cutoff values that can partition the study population into two groups with substantially distinct progression-free survival (PFS) and overall survival (OS) outcomes were determined. The relationship between PIV values and OS outcomes was the primary outcome measure. Eighty-nine eligible patients were divided into two PIV groups at an optimal cutoff of 417 [Area under curve (AUC): 73.2%; sensitivity: 70.4%; specificity: 66.7%]: Group 1: PIV < 417 ( = 36) and Group 2: PIV ≥ 417 ( = 53). Comparative analyses revealed that patients with PIV < 417 had significantly longer OS (25.0 vs 14.0 months, < .001) and PFS (18.0 vs 8.9 months, = .004) compared to patients with PIV ≥ 417. The outcomes of the multivariate analysis have verified the independent significance of pretreatment PIV concerning PFS ( < .001) and OS ( < .001) outcomes. The findings of this retrospective study indicate that the pretreatment PIV is a reliable and independent prognostic biomarker for patients with LS-SCLC who were treated with C-CRT and PCI.
我们的研究目的是评估在接受局限期小细胞肺癌（LS-SCLC）同步放化疗（C-CRT）和预防性颅脑照射（PCI）之前，全免疫炎症值（PIV）对预后的预测意义。回顾性分析了 2010 年 1 月至 2021 年 12 月期间接受 C-CRT 和 PCI 的 LS-SCLC 患者的病历。PIV 值通过治疗前 7 天内获得的外周血样本计算得出：PIV = [中性粒细胞×血小板×单核细胞]÷淋巴细胞。使用受试者工作特征（ROC）曲线分析，确定能够将研究人群分为两组的最佳预处理 PIV 截断值，两组患者的无进展生存（PFS）和总生存（OS）结局有显著差异。PIV 值与 OS 结局之间的关系是主要的研究终点。89 名符合条件的患者根据 417 的最佳截断值分为两组：PIV＜417（n=36）和 PIV≥417（n=53）。对比分析显示，PIV＜417 的患者 OS（25.0 个月比 14.0 个月， ＜.001）和 PFS（18.0 个月比 8.9 个月， =.004）明显长于 PIV≥417 的患者。多变量分析的结果证实了预处理 PIV 对 PFS（ ＜.001）和 OS（ ＜.001）的独立预测意义。这项回顾性研究的结果表明，在接受 C-CRT 和 PCI 治疗的 LS-SCLC 患者中，PIV 是一种可靠的独立预后生物标志物。
